Mit Magzter GOLD unbegrenztes Potenzial nutzen

Mit Magzter GOLD unbegrenztes Potenzial nutzen

Erhalten Sie unbegrenzten Zugriff auf über 9.000 Zeitschriften, Zeitungen und Premium-Artikel für nur

$149.99
 
$74.99/Jahr
The Perfect Holiday Gift Gift Now

“We have the capacity to produce over 10M COVID-19 tests per week globally”

Bio Spectrum

|

October 2020

Thermo Fisher Scientific, the world leader in serving science, is continuously working to expand global capacity and capabilities across its leading pharma services network to support customers in government, industry and academia as they accelerate development and production of COVID-19 vaccines, therapies and other treatments.

- Dr Manbeena Chawla

“We have the capacity to produce over 10M COVID-19 tests per week globally”

The company is now supporting over 200 projects globally. The company is also supporting multiple vaccine programmes globally that are in or entering human clinical trials, providing critical capacity and expertise that has accelerated development and readiness by months. In addition to its work on COVID-19-related vaccines and therapies, the company continues to ensure that patients undergoing clinical trials continue to receive the critical medicines they need during this crisis. Amit Chopra, Managing Director, India and Middle East, Thermo Fisher Scientific, Mumbai recently spoke to BioSpectrum about the company’s initiatives to counter COVID-19, particularly in India. Edited excerpts;

How is Thermo Fisher Scientific expanding its diagnostic capacity to fight the global pandemic?

At Thermo Fisher Scientific, our mission is to enable our customers to make the world healthier, cleaner, and safer. Globally, we saw a significant increase in the spread of the virus and our customers were getting inundated. As reliable partners, our primary objective was to scale our offerings to enable them to better navigate through this pandemic. We have been actively involved in understanding the structure of the virus, developing new diagnostic tests, providing personal protective equipment, reagents, and other laboratory essential instruments, to providing tools for vaccine research and development, clinical trials and even manufacturing some of the therapeutics. TaqPath COVID-19 Combo Kits were one of the first tests to receive Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) and are being extensively used across the world.

WEITERE GESCHICHTEN VON Bio Spectrum

Bio Spectrum

Bio Spectrum

India's Strategic Shift Towards High-Quality, Low-Cost MedTech

India's healthcare infrastructure continues to face significant strain from the rising prevalence of non-communicable diseases (NCDs), contributing around 66 per cent of the mortalities in the country, underscoring the need for scalable continuous monitoring, early diagnosis, and therapeutic devices. Yet, advanced imaging systems, analysers, surgical tools, or robotic devices remain very expensive due to import reliance, high logistics costs, and maintenance/ service contracts. Segments showing strongest traction today are diagnostics (point-of-care devices, rapid tests, compact imaging devices), remote monitoring/wearable devices, and therapeutic devices such as surgical robotic systems, renal care systems, and wound care devices.

time to read

4 mins

December 2025

Bio Spectrum

Bio Spectrum

How India's Diabetes Crisis is Driving Med Devices Market

A growing diabetic population in India is a blessing for the care devices market. Both Indian and global diabetes care devices have taken this growing demand for various devices, kits as an opportunity to expand their market share. But the scope in rural areas seems a bit challenging for various companies due to less awareness about the disease, affordability etc. Let's look at this growing diabetes care devices market.

time to read

9 mins

December 2025

Bio Spectrum

Thermo Fisher Scientific invests Rs 160 Cr+ to expand Bengaluru R&D facility

Thermo Fisher Scientific's expanded Research and Development (R&D) Centre of Excellence was inaugurated in Bengaluru by Sanjeev Kumar Gupta, CEO, Karnataka Digital Economy Mission (KDEM).

time to read

1 min

December 2025

Bio Spectrum

Bio Spectrum

Motorica strengthens India presence with appointment of Kavinder Beniwal as COO

Motorica, a Delhi-based medtech company specialising in assistive technologies and medical cybernetics, has announced the appointment of Kavinder Beniwal as Chief Operational Officer (COO) of Motorica India.

time to read

1 min

December 2025

Bio Spectrum

Bio Spectrum

Cabinet approves major expansion of PG and UG medical education capacity

Union Cabinet chaired by the Prime Minister Narendra Modi has approved the Phase-Ill of the Centrally Sponsored Scheme (CSS) for strengthening and upgradation of existing State Government/ Central Government Medical Colleges/Standalone PG Institutes/ Government Hospitals for increasing 5,000 PG seats and extension of the CSS for upgradation of existing government medical colleges for increasing 5,023 MBBS seats with an enhanced cost ceiling of Rs 1.5 crore per seat.

time to read

1 min

December 2025

Bio Spectrum

Bio Spectrum

Dr Sharvil Patel steps in as Indian Pharmaceutical Alliance President

The Indian Pharmaceutical Alliance (IPA) has announced a leadership transition, with Dr Sharvil Patel, Managing Director of Zydus Lifesciences and former Vice President of IPA, assuming the role of President.

time to read

1 min

December 2025

Bio Spectrum

Bio Spectrum

PAG-led Sekhmet Pharmaventures announces appointment of Mukesh Agarwal as CFO

Hyderabad-based Sekhmet Pharmaventures, a fast-emerging global API/CDMO player led by leading Asia-focused investment firm PAG, has announced the appointment of Mukesh Agarwal as its new Chief Financial Officer (CFO).

time to read

1 min

December 2025

Bio Spectrum

Monash University Malaysia and Tata Chemicals forge healthcare researchfocused partnership

The importance of gastrointestinal health is a key focus for researchers and innovators, as highlighted by the partnership between Monash University Malaysia and Tata Chemicals Limited.

time to read

1 min

December 2025

Bio Spectrum

Bio Spectrum

"India has the talent and ambition to lead globally in advanced therapies, biologics, and oncology"

Thermo Fisher Scientific has recently announced plans to make significant investments in India's biopharma infrastructure, with new facilities that will enhance the biopharma manufacturing capabilities. Central to this expansion strategy are two major facilities in Genome Valley, Hyderabad, i.e. Bioprocess Design Center (BDC), and Customer Experience Center (CEC). In addition, the company has invested more than Rs 160 crore this year to expand its R&D facility in Bengaluru. For further understanding on these new developments, BioSpectrum spoke in detail to Srinath Venkatesh, Managing Director, India & South Asia, Thermo Fisher Scientific. Edited excerpts;

time to read

4 mins

December 2025

Bio Spectrum

Bio Spectrum

"AI is a transformative enabler that's reshaping how science is conducted in labs"

2025 witnessed multiple new initiatives taken by Agilent Technologies, a global leader in life sciences, diagnostics, and applied chemical markets, for the Indian market. These initiatives included establishment of an India Solutions Center in Manesar; and a Biopharma Experience Center in Hyderabad. 2025 also saw Nandakumar Kalathil stepping in as the new Country General Manager for Agilent India. With over 25 years of experience in the analytical industry, Nanda brings extensive expertise in leadership, team management, and customer relations. To find out more about the company's growth plans in 2026 in India, BioSpectrum interacted with Nandakumar Kalathil, Country General Manager for Agilent India in detail. Edited excerpts:

time to read

4 mins

December 2025

Translate

Share

-
+

Change font size

Holiday offer front
Holiday offer back